COPENHAGEN, Denmark, September 16, 2021 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transaction of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.
More...
CMS Home Page
-
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
-
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer
KØBENHAVN, Danmark, 16. september 2021 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktion med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse.
More... -
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, September 10, 2021 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.
More... -
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer
KØBENHAVN, Danmark, 10. september 2021 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse.
More... -
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
COPENHAGEN, Denmark, September 8, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 2,478,690 as a consequence of employees’ exercise of warrants.
More... -
Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udnyttelse af tegningsoptioner
KØBENHAVN, Danmark, 8. september 2021 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har forhøjet sin aktiekapital med nominelt DKK 2.478.690 som følge af medarbejderes udnyttelse af tegningsoptioner.
More... -
Bavarian Nordic Reports Positive Results from Human Challenge Trial of its RSV Vaccine Candidate
COPENHAGEN, Denmark, September 1, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today results from a human challenge trial of the RSV vaccine candidate, MVA-BN® RSV. The phase 2 double-blinded, placebo-controlled trial enrolled healthy adult volunteers, 18-50 years of age who were randomized to receive either a single vaccination of MVA-BN RSV or placebo. Volunteers were challenged intranasally with an RSV type A strain 28 days after vaccination. A total of 61 subjects were evaluable.
... -
Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine
COPENHAGEN, Denmark, August 23, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a Phase 2 clinical trial of its COVID-19 vaccine candidate, ABNCoV2. The trial will investigate the potential of ABNCoV2 as a booster vaccine for individuals with previous COVID-19 disease or vaccination.
More... -
Bavarian Nordic modtager finansiering fra det danske sundhedsministerium til videreudvikling af COVID-19 boostervaccine
KØBENHAVN, Danmark, 23. august 2021 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en aftale med det danske sundhedsministerium (”Sundhedsministeriet”) om finansiering af videreudviklingen af selskabets COVID-19 vaccinekandidat, ABNCoV2.
More...
There are no articles in this category.
Please log in to your account to view your subscribed posts.